Aquestive Therapeutics
AQST
56 hedge funds and large institutions have $101M invested in Aquestive Therapeutics in 2019 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 7 closing their positions.
300% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 7
134% more capital invested
Capital invested by funds: $43.2M → $101M (+$57.9M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
60% more funds holding
Funds holding: 35 → 56 (+21)
0.23% more ownership
Funds ownership: 54.25% → 54.47% (+0.23%)
0% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$3.84M |
| 2 |
WCM
Wildcat Capital Management
New York
|
+$2.37M |
| 3 |
EP
Eversept Partners
New York
|
+$1.82M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.63M |
| 5 |
D.E. Shaw & Co
New York
|
+$1.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$934K |
| 2 |
BlackRock
New York
|
-$866K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$464K |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$317K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
-$188K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citigroup
New York
| $4K | -$255 | -49 | -7% |
|
|
AG
52
Advisor Group
Phoenix,
Arizona
| $1K | -$18.4K | -3,546 | -96% |
|
53
Barclays
London,
United Kingdom
| $1K | -$3.39K | -652 | -80% |
|
|
EWM
54
Edge Wealth Management
New York
| $1K | – | – | – |
|
|
PHK
55
Point72 Hong Kong
Hong Kong
| $1K | +$593 | +114 | New |
|
56
BNP Paribas Financial Markets
Paris,
France
| $262 | -$7.04K | -1,354 | -97% |
|
|
57
Massachusetts Financial Services
Boston,
Massachusetts
| – | -$934K | -293,625 | Closed |
|
|
BBA
58
Baker Bros. Advisors
New York
| – | -$317K | -99,600 | Closed |
|
59
Acadian Asset Management
Boston,
Massachusetts
| – | -$61K | -19,090 | Closed |
|
60
Russell Investments Group
London,
United Kingdom
| – | -$46K | -14,625 | Closed |
|
|
MWNA
61
Marshall Wace North America
New York
| – | -$26K | -8,100 | Closed |
|
62
Victory Capital Management
San Antonio,
Texas
| – | -$10K | -3,148 | Closed |
|
63
Daiwa Securities Group
Tokyo,
Japan
| – | -$1K | -163 | Closed |
|
AQST Hedge Fund Activity: Q4 2019 in Review
56 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q4 2019, worth a combined $101M — up 134% from $43.2M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new AQST positions and 7 closed out — a net gain of 21 holders — while 12 added to existing stakes and 12 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $3.84M. The largest seller was Massachusetts Financial Services, exiting entirely with an estimated $934K sold.
- 56 institutional investors held Aquestive Therapeutics (AQST) as of Q4 2019, up from 35 in Q3 2019.
- Funds reported $101M of Aquestive Therapeutics stock for Q4 2019, up 134% quarter-over-quarter.
- 28 funds opened new Aquestive Therapeutics positions in Q4 2019 and 7 closed out, a net change of +21 holders.
- The largest Aquestive Therapeutics buyer in Q4 2019 was Opaleye Management, an estimated $3.84M added.
- The largest Aquestive Therapeutics seller in Q4 2019 was Massachusetts Financial Services, an estimated $934K sold.
Based on aggregated 13F filings for Q4 2019.